Podcasts about Market access

Stephen Grootes speaks to Zihaad Israfil, CEO of CFI South Africa, about how digital platforms are empowering younger investors with direct market access and educational tools. The Money Show is a podcast hosted by well-known journalist and radio presenter, Stephen Grootes. He explores the latest economic trends, business developments, investment opportunities, and personal finance strategies. Each episode features engaging conversations with top newsmakers, industry experts, financial advisors, entrepreneurs, and politicians, offering you thought-provoking insights to navigate the ever-changing financial landscape.    Thank you for listening to a podcast from The Money Show Listen live Primedia+ weekdays from 18:00 and 20:00 (SA Time) to The Money Show with Stephen Grootes broadcast on 702 https://buff.ly/gk3y0Kj and CapeTalk https://buff.ly/NnFM3Nk For more from the show, go to https://buff.ly/7QpH0jY or find all the catch-up podcasts here https://buff.ly/PlhvUVe Subscribe to The Money Show Daily Newsletter and the Weekly Business Wrap here https://buff.ly/v5mfetc The Money Show is brought to you by Absa     Follow us on social media   702 on Facebook: https://www.facebook.com/TalkRadio702 702 on TikTok: https://www.tiktok.com/@talkradio702 702 on Instagram: https://www.instagram.com/talkradio702/ 702 on X: https://x.com/CapeTalk 702 on YouTube: https://www.youtube.com/@radio702   CapeTalk on Facebook: https://www.facebook.com/CapeTalk CapeTalk on TikTok: https://www.tiktok.com/@capetalk CapeTalk on Instagram: https://www.instagram.com/ CapeTalk on X: https://x.com/Radio702 CapeTalk on YouTube: https://www.youtube.com/@CapeTalk567 See omnystudio.com/listener for privacy information.

Many MedTech companies focus heavily on FDA clearance but overlook a critical layer of U.S. market entry: state-level compliance. In this episode, Etienne Nichols speaks with Adam Steadman, CEO of MDD Options, to unpack the real-world challenges that derail commercialization after regulatory approval. From navigating state-specific registration, sales tax laws, and distribution logistics to choosing between direct and distributor-based strategies, Adam shares hard-earned insights for avoiding the "second valley of death" post-clearance. Whether you're a domestic startup or an international company entering the U.S., this episode arms you with a tactical understanding of compliance landmines and scalable go-to-market strategies.Key Timestamps00:02 – Intro: The real MedTech “valley of death” after FDA clearance04:45 – Why U.S. state-level registration is misunderstood and overlooked08:15 – State-level definitions of medical devices and why they differ11:20 – Strategic go-to-market options: Distribution vs. Direct17:00 – How regulations vary drastically by state (CA, TX, etc.)21:50 – The real risks of noncompliance: lawsuits, bad PR, and due diligence failures26:15 – Why distribution agreements can stall your growth (and how to avoid it)34:30 – Sales tax & use tax: The hidden compliance trap39:10 – Logistics, warehousing, and long-term liabilities in contracts44:55 – Overlooked pitfalls: Secretary of State filings and income tax in 36+ states51:15 – Software as a Medical Device (SaMD): U.S. compliance still applies55:30 – Selling to the U.S. government vs. private sector buyers59:20 – Veterinary devices and why they still need regulatory controls1:03:10 – What a winning go-to-market strategy actually looks like1:10:25 – Adam's final advice to MedTech startups (foreign and domestic)Standout Quotes"You're not entering one country—you're entering 50 states and D.C. Each with its own rules, definitions, and tax laws."—Adam Steadman explains why U.S. MedTech entry requires a state-by-state strategy, especially for international companies."None of the strategics want your warehouse management system—they want your product, your sales, and your proof of market fit."—Steadman on why building non-core infrastructure slows down commercialization and valuation.Top 5 TakeawaysFDA Clearance ≠ Market Readiness – State-level registrations, sales tax laws, and pharmacy board definitions often delay or block commercialization.Distribution Isn't Always a Shortcut – National distributors may have misaligned incentives and can lock you into exclusivity that hinders growth.Sales Tax is a Regulatory Minefield – 46 states require separate sales tax registration, exemptions tracking, and monthly filings—even if you're tax-exempt.Beware of Long-Term Contracts – Logistics and distribution contracts often lock companies into rigid terms that prevent pivots or acquisitions.Speed to Market Is Strategic – Getting to market fast is often the difference between becoming #1 or #3—and #3 often gets nothing.MedTech 101What Is “Nexus” and Why It Matters for Sales Tax?“Nexus” refers to the minimum level of economic activity that triggers tax obligations in a given state. For example, selling $100,000 of devices or 200 transactions may establish nexus, requiring you to register for sales tax. Unlike VAT in Europe, U.S. sales tax laws are state-specific, making this a major compliance hurdle for MedTech companies.References & Resources

Julio G. Martinez-Clark CEO of Bioaccess and President of IAOCR/GCSA Americas is a MedTech trailblazer helping startups accelerate First-in-Human (FIH) clinical trials across Latin America, with over 20 years of experience spanning healthcare, telecom and venture capitalIn this episode, we unpack why more MedTech companies are turning to LATAM for faster, more cost-effective trial execution. Julio shares how his Miami-based CRO helps deliver 58-day CE mark approvals, his experience supporting 100+ device startups and why time, not money, is the most precious currency for early-stage founders. We also touch on trial quality, regulatory strategy and why he believes Latin America will play a defining role in the next era of global MedTech innovationTimestamps:[00:00:47] Why LATAM Is the Next MedTech Trial Hub[00:02:21] The Problem with FIH Trials in the U.S.[00:04:42] How bioaccess® Reduces Approval Timelines by 70%[00:06:01] Strategic Sites, Patient Retention & CRO Infrastructure[00:08:17] Do LATAM Trials Hold Up to FDA & EU Scrutiny?[00:10:43] The Fundraising Pressure Behind Faster Clinical Results[00:12:22] Founder Mistakes in In-House Trial Management[00:14:11] Why LATAM May Overtake Eastern Europe in FIH Volume[00:17:26] Regulatory Standards, UNESCO, and Regional Quality[00:20:10] Julio Outside the Office: Family, Fitness & PodcastingGet in touch with Julio - https://www.linkedin.com/in/juliomartinezclark/Learn more about Bioaccess - https://www.bioaccessla.com/ Get in touch with Karandeep Badwal - https://www.linkedin.com/in/karandeepbadwal/ Follow Karandeep on YouTube - https://www.youtube.com/@KarandeepBadwalSubscribe to the Podcast

In this special edition of The Distribution, host Brandon Sedloff sits down with Chris Tinsley and Rory Mabin of NASDAQ's fund secondaries business, recorded live from NASDAQ's Times Square studio.  The conversation unpacks the evolution of the fund secondaries market, highlighting how NASDAQ is bringing technology, transparency, and regulatory clarity to a historically opaque and manual process. Chris and Rory share how their unique professional journeys—from institutional investing to pioneering fintech—positioned them to rethink secondary liquidity in private markets.  They dive deep into the complexities of LP transactions, the origins of NASDAQ's platform, and the structural and regulatory innovations making scaled, GP-sponsored liquidity a reality today. They discuss: * How NASDAQ's acquisition of SecondMarket evolved into a fund secondaries platform * Why secondary LP transactions are more like M&A deals than stock trades * The value of “GP-sponsored” liquidity programs and how they differ from GP-led deals * How NASDAQ's Qualified Matching Service (QMS) helps GPs avoid tax complications while scaling liquidity * Why scalable technology and a growing buyer base—including family offices and institutional LPs—are reshaping the future of private market secondaries This episode is essential listening for GPs navigating LP liquidity needs or building next-gen fund structures in private markets. Links: Nasdaq Fund Secondaries - https://www.nasdaq.com/solutions/fund-secondaries Chris Tinsley on LinkedIn - https://www.linkedin.com/in/christoffertinsley/ Rory Mabin on LinkedIn - https://www.linkedin.com/in/rory-mabin-966a1333/ Brandon on LinkedIn - https://www.linkedin.com/in/bsedloff/ Juniper Square - https://www.junipersquare.com/ Topics: (00:00:00) - Intro (00:01:20) - Introducing Chris Tinsley and Rory Mabin (00:01:45) - NASDAQ's role in private market secondaries (00:02:09) - Chris Tinsley's journey to NASDAQ (00:03:55) - Rory Mabin's background in fund secondaries (00:05:04) - Understanding NASDAQ beyond the exchange (00:06:40) - The origin of NASDAQ's fund secondaries business (00:10:28) - Challenges in fund secondaries transactions (00:17:40) - The role of technology in streamlining processes (00:23:49) - Adapting to investor needs in private markets (00:27:26) - Enhanced liquidity options for limited partnerships (00:31:02) - Understanding Qualified Matching Service (QMS) (00:33:28) - Challenges and solutions in providing liquidity (00:36:52) - The role of technology in liquidity solutions (00:38:03) - Practical implementation of embedded liquidity (00:46:37) - The future of secondary markets and AI integration (00:50:02) - Conclusion and final thoughts

In this special edition of the Syneos Health Podcast recorded from the floor of Asembia's AXS25 Summit, host Michael Sarshad sits down with Kim Plesnarski, SVP of Market Access and Patient Support Services at Syneos Health and Kelly Carter, AVP of Patient Support at Amgen, to unpack the evolving landscape of patient support. The discussion explores the blurring lines between general and specialty medicine, the growing administrative burden on providers and the need to embed seamless, tech-enabled support into the healthcare journey. The trio dives into the role of Field Reimbursement Managers (FRMs), payer challenges, affordability barriers and how AI and automation are beginning to transform operations—from personalized patient education to proactive intervention. If you're interested in how manufacturers can shift from reactive to proactive models and scale personalized support in an increasingly complex environment, this episode is a must-listen.The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you'll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health. Like what you're hearing? Be sure to rate and review us! We want to hear from you! If there's a topic you'd like us to cover on a future episode, contact us at podcast@syneoshealth.com.

„Setz dich mal auf die andere Seite des Tisches“ – unter diesem Motto blickt Hanns Kratzer, Jurist und Market Access-Experte, gemeinsam mit Host Dominik Flener auf zwei Jahrzehnte Erstattungskodex zurück. Dabei analysieren die beiden, wo das System heute steht und wo es an seine Grenzen stößt – und stellen sich gleichzeitig der Frage: Wie kommt Innovation überhaupt bei Patient:innen an? Denn Market Access ist kein Zahlenspiel – es ist ein Balanceakt zwischen Innovation, Versorgung und Systemlogik. Diese Episode verknüpft fundierten Rückblick mit aktuellem Ausblick: Vom Bewertungsboard bis zur No-Box, vom AHPN über Hochpreiser bis zu den Herausforderungen an der Schnittstelle zwischen Spital und niedergelassenem Bereich – ein klarer, praxisnaher Blick hinter die Kulissen.  Highlights dieser Folge:Warum das System oft nicht „böse“, sondern einfach überfordert istWas der Erstattungskodex kann – und wo die Verwaltungspraxis seinen ursprünglichen Geist verwässertWie aus Parallelimporten plötzlich Millionen-Risiken für Hersteller werdenWarum ein Hochpreiser-Team kein Verwaltungsmonster, sondern ein Versorgungsturbo sein kannWie PVEs zeigen, dass regionale Lösungen oft mehr bewirken als nationale StrategienUnd warum die wichtigste Fähigkeit im Market Access Empathie ist – für alle Stakeholder Diese Episode ist Pflicht für alle, die in der Gesundheitsversorgung mitreden – oder endlich verstehen wollen, wie viele Perspektiven im Market Access bereich wirklich zusammenspielen.+++ Links zur Episode +++HCC Lehrgang: Market Access & Reimbursement+++ Feedback & Social Media +++Du hast Feedback zu dieser Episode?Schreibe uns gerne an podcast@healthcarechangers.com.Folge dem Host Dominik FlenerLinkedIn | Facebook | InstagramFolge dem Healthcare Changers PodcastLinkedIn | Facebook | Instagram++++++

In this episode of our Navigating Modern Market Access series, recorded from the floor of Asembia's AXS25 Summit, host Sara Rubin sits down with Rob Truckenmiller, the newly appointed CEO of PharmaCord. Drawing from his deep experience across small, mid-sized and large pharmaceutical companies, Rob explores how market access strategies must evolve to meet today's healthcare challenges. From the integration of patient services and payer strategies to the role of technology and data in shaping outcomes, Rob shares his perspective on how pharma companies can empower patients, optimize gross-to-net and navigate the complex US healthcare landscape. Tune in for actionable insights on building a smarter, more patient-centric access model.The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you'll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health. Like what you're hearing? Be sure to rate and review us! We want to hear from you! If there's a topic you'd like us to cover on a future episode, contact us at podcast@syneoshealth.com.

In this special edition of the Syneos Health Podcast recorded from the floor of Asembia's AXS25 Summit, host Michael Sarshad speaks with Kim Plesnarski, SVP of Market Access and Patient Support Services at Syneos Health and Greg Morris, Chief Strategy Officer at CareMetx. They explore the latest trends shaping patient support services—from the surge of AI-powered solutions to the shift toward hybrid hub models. The conversation dives into the challenges of reactive support programs, the need for continual innovation and the nuanced debate between insourcing and outsourcing. With practical insights and real-world examples, Kim and Greg share strategies for building scalable, tech-forward patient service models that meet the evolving demands of both patients and providers.The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you'll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health. Like what you're hearing? Be sure to rate and review us! We want to hear from you! If there's a topic you'd like us to cover on a future episode, contact us at podcast@syneoshealth.com.

Early access programmes (EAPs) for novel medicines are an often-misunderstood strategy outside of western markets. In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Cem Zorlular, CEO of Er-Kim Pharmaceuticals, a company that has been serving as a regional affiliate for pharma and biotech since 1981 in the CEE and Mediterranean. Market access strategies in many international markets do not function the same way as they do in the US or Western Europe and require a different approach. Zorlular explains how EAPs can drive revenue for pharmaceutical companies from international unlicensed markets, but that most importantly EAPs allow patients access to life-altering novel medicines. What's more, he says, EAPs can also help shape the biotech space by supporting the opportunity for RWD collection outside of the clinical trial setting and build momentum with local payers, regulators, and the medical community. You can listen to episode 179a of the pharmaphorum podcast in the player below, download the episode to your computer, or find it - and subscribe to the rest of the series - in iTunes, Spotify, Amazon Music, Podbean, and pretty much wherever you get your other podcasts!

This is Zack Fuss. Today, we are breaking down Interactive Brokers, widely recognized as IBKR. Founded in 1978, Interactive Brokers evolved from a market maker on the American Stock Exchange to a global, cutting-edge electronic brokerage firm. Its founder, Thomas Peterffy, remains far and away its largest shareholder and has earned his place as one of the wealthiest people in the world. To break down IBKR, I'm joined by Freddie Lait and Jacopo Di Nardo of Latitude Investment Management. We explore the journey of IBKR from its early days as Timber Hill to its current status as a publicly traded company with a market cap of nearly $80 billion. We also discuss their differentiated tech stack, their global reach, and their famously low fees. Please enjoy this breakdown of Interactive Brokers. Subscribe to Colossus Review For the full show notes, transcript, and links to the best content to learn more, check out the episode page here. —- This episode is brought to you by Octus, formerly Reorg, is the essential credit intelligence and data provider for nearly 40,000 professionals across the world's leading buy side firms, investment banks, law firms and advisory firms. By surrounding unparalleled human expertise with embedded AI technology, data and workflow tools, Octus unlocks powerful truths that fuel decisive action in financial markets. Visit octus.com to learn how rigorously verified intelligence is delivered at speed to create a complete picture across the entire credit lifecycle.  —- Business Breakdowns is a property of Colossus, LLC. For more episodes of Business Breakdowns, visit joincolossus.com/episodes. Editing and post-production work for this episode was provided by The Podcast Consultant (https://thepodcastconsultant.com). Show Notes (00:00:00) Welcome to Business Breakdowns (00:03:41) Overview of Interactive Brokers (00:04:53) Revenue Streams and Business Model (00:06:15) Competitive Landscape and Differentiation (00:08:38) Founder Thomas Peterffy's Story (00:11:31) Payment for Order Flow and Market Access (00:13:41) Automation and Risk Management (00:16:50) Customer Experience and Balance Sheet Strategy (00:26:33) Growth Opportunities and International Expansion (00:34:34) Valuation and Financial Metrics (00:37:28) Risks and Stress Tests (00:42:13) Lessons From IBKR

After losing both her sister and a close friend to cancer in the same year, Carissa Rollins knew she couldn't stay where she was. As CIO of UnitedHealthcare, she had scale and power, but not proximity to the technology that might have changed those outcomes. So when the call came from Illumina, a company pioneering genomic sequencing, she listened. And then she leapt. In this episode of Inspiring Women with Laurie McGraw, Carissa shares how grief reshaped her career and how purpose—not title—has always been her compass. She talks candidly about what it means to walk away from the “biggest job of your life” to chase deeper impact, and how she's now using her insider knowledge of the payer system to open doors for patients who would otherwise be left out of the genomic revolution. Carissa also reflects on the turning points that built her leadership style—from writing a three-page letter to fight for a promotion, to insisting on coaching even when her boss said she didn't need it. She's quick to credit the mentors who pulled her forward—but equally passionate about pulling others up behind her. “Why are you sitting in the back?” she recalls asking one young woman. “Your voice is important.” Now at Illumina, she's helping her teams think critically about how AI can reduce burnout—not by cutting jobs, but by removing outdated, burdensome processes and freeing people to do more meaningful work. It's a nuanced, systems-based view that resists the hype and centers on impact. You'll also hear Carissa speak on: Why she sees restlessness as a sign it's time to grow The alarming drop in women in tech—and what we can do about it How the Grand Canyon Conservancy helps her stay grounded (and where she thinks tech could help the parks) What it really takes to make space at the table—and why women can't afford to close the door behind them This conversation is full of hard-earned wisdom, honest reflections, and a fierce belief in using every ounce of power to move others forward. Chapters 03:52 Overcoming Restlessness & Seeking New Challenges 10:05 Impact, Market Access & Personal Fulfillment 14:59 AI's Role in Operations & Efficiency 15:53 Inspiring Young Women in Technology 17:38 Challenges & Setbacks for Women in Tech 19:52 Empowering Advice for Future Leaders Guest & Host Links Connect with Laurie McGraw on LinkedIn Connect with Carissa Rollins on LinkedIn About Illumina Connect with Inspiring Women Browse Episodes | LinkedIn | Instagram | Apple | Spotify This episode of Inspiring Women with Laurie McGraw was recorded at the WBL Summit, a leadership, networking, and professional development conference for WBL members that takes place each spring. WBL is a network of 1500+ senior executive women in healthcare who convene to share ideas, make valuable connections, and solve business challenges. WBL's mission is to connect and support our members in advancing their careers and impact on our industry.

Graeme Raubenheimer is in conversation with Abrie Rautenbach - Head of Absa AgriBusiness, about the immediate future of South Africa’s citrus industry – this on the back of impending tariffs from the US, but a growing demand elsewhere in the world. Afternoon Drive with John Maytham is the late afternoon show on CapeTalk. Presenter John Maytham is an actor and author-turned-talk radio veteran and seasoned journalist. His show serves a round-up of local and international news coupled with the latest in business, sport, traffic and weather. The host’s eclectic interests mean the program often surprises the audience with intriguing book reviews and inspiring interviews profiling artists. A daily highlight is Rapid Fire, just after 5:30 pm. CapeTalk fans call in, in an attempt to stump the presenter with their general knowledge questions. Another firm favourite is the humorous Thursday crossing with award-winning journalist Rebecca Davis, called “Plan B”. Thank you for listening to a podcast from Afternoon Drive with John Maytham Listen live – Afternoon Drive with John Maytham is broadcast weekdays between 15:00 and 18:00 (SA Time) https://www.primediaplus.com/station/capetalk Find all the catch-up podcasts here https://www.primediaplus.com/capetalk/afternoon-drive-with-john-maytham/audio-podcasts/afternoon-drive-with-john-maytham/ Subscribe to the CapeTalk daily and weekly newsletters https://www.primediaplus.com/competitions/newsletter-subscription/ Follow us on social media: CapeTalk on Facebook: www.facebook.com/CapeTalk   CapeTalk on TikTok: www.tiktok.com/@capetalk   CapeTalk on Instagram: www.instagram.com/capetalkza  CapeTalk on X: www.x.com/CapeTalk  CapeTalk on YouTube: www.youtube.com/@CapeTalk567  See omnystudio.com/listener for privacy information.

Donate (no account necessary) | Subscribe (account required) Join Bryan Dean Wright, former CIA Operations Officer, as he breaks down today's biggest stories shaping America and the world. Trump's First 100 Days: Achievements and Challenges – President Trump celebrates 100 days in office with mixed polling results. While Democrats move to impeach him, fresh data shows Trump is still preferred over Democrats on key issues like immigration and national security. Meanwhile, the U.S. economy shows resilience despite tariff pressures, though supply chain concerns loom. Border Security Milestone: Near Total Control Achieved – Only nine migrants have been released into the U.S. during Trump's term so far, compared to 9,000 daily under Biden. The administration is also building a massive new database to target millions of illegal immigrants for deportation. Houthis Use Chinese Intel to Strike U.S. Navy – A Chinese satellite company supplied intelligence that helped the Houthis target the USS Harry Truman in the Red Sea, leading to the loss of a $60 million Navy jet. Bryan calls for a tougher U.S. response to China's proxy aggression. Spain's Massive Blackout Raises Cyberattack Fears – Spain suffers a nationwide power outage, prompting concerns about Russian cyberattacks and vulnerabilities tied to green energy dependence. Bryan warns listeners to prepare for disruptions. China's Sneaky Plan to Evade Trump Tariffs – Chinese companies are working through Indian intermediaries to bypass U.S. tariffs, highlighting both the resilience of global markets and the need for a more effective American reshoring strategy. Bryan proposes offering Indian companies incentives to establish factories in the US instead. Get the facts, the analysis, and the truth - only on The Wright Report. "And you shall know the truth, and the truth shall make you free." - John 8:32​

Send us a textDiscover how health economics can support successful Medical Device launch, proposition development, and market accessThis episode offers an insightful journey into the world of medical device market access. Specialists from our health economics and market access teams explore the hidden challenges faced by medical devices companies when taking new innovations to healthcare leaders, communicating value and demonstrating evidence, and offer tips on leveraging health economics for a successful launch.Juliet Wallace (Senior Partnerships Coordinator) delves deep with our expert panel into the pivotal role of health economic evaluation in supporting market access for medical devices. Juliet puts audience questions to Hannah Palin (Director, Local Market Access), Calum Jones (Associate Director, Health Economics), and Evelyne Priestman (Consultant, Health Economics).See full details at: https://mtechaccess.co.uk/launch-strategies-health-economic-modelling-medical-devices/This episode was originally broadcast live as webinar in February 2025. https://petauri.com/Subscribe to our newsletter to hear more news, insights and events from Petauri Evidence

The biopharma market is booming—but not without turbulence. In this kickoff episode of our special podcast series in collaboration with Asembia, hosts Michael Sarshad, Managing Director, Commercial Advisory, Syneos Health and Sara Rubin, Senior Vice President, Market Access Strategy at Spherico, a Syneos Health company, unpack the dynamic forces reshaping how therapies reach patients. Recorded ahead of Asembia's AXS25 Specialty Pharmacy Summit, they dive into the impact of tariffs, the power of AI in streamlining patient support, the ripple effects of the Inflation Reduction Act and how digital transformation is changing the way manufacturers engage population health decision-makers. Tune in for expert insights, preview topics for this year's summit, and discover how the industry is responding to rising complexity with strategic innovation.The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you'll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health. Like what you're hearing? Be sure to rate and review us! We want to hear from you! If there's a topic you'd like us to cover on a future episode, contact us at podcast@syneoshealth.com.

07 Apr 2025 - The Final Steps in Drug Development and Market Access

Chip Moebus, VP Market Access, joined the Chase MedSearch Podcast to discuss the difficulties of getting accurate data for epileptic patients on the type of epileptic seizure they've suffered and the frequency rate. He further discussed how the Minder System has the potential to provide extraordinarily insightful data that Neurologists have never been able to capture before.    www.epiminder.com

In this episode, host Mitch Robbins interviews Mickey Brown, Vice President of Access and Reimbursement at Cerapedics, discussing his 30+ year career journey and insights on healthcare market access.Key Highlights:Mickey shares his transition from 15 years on the payer side (Blue Cross, United Healthcare) to manufacturer roles at Medtronic, Cochlear, and now CerapedicsLearn how stepping outside his comfort zone at critical moments propelled his career forwardDiscover the biggest challenges facing market access professionals in 2025Understand common reimbursement strategy mistakes companies make and how to avoid themPractical Takeaways:Why waiting too long to develop reimbursement strategy hurts product launchesThe key differences between director and VP-level thinkingWhat makes an outstanding market access professionalHow to effectively engage with increasingly inaccessible payersWhether you're in medical device sales, reimbursement, or aspiring to leadership roles in healthcare, this conversation offers valuable insights from both sides of the healthcare ecosystem.

Chinese Premier Li Qiang has reiterated the country's commitment to openness and global collaboration, saying China will further expand market access for foreign investors.

In this episode, I welcome back Necdet Gunsoy, who's now in a new role as the founder of EviMed, a boutique consultancy specializing in health economics, outcomes research, real-world evidence, and market access. We dive into the often tense relationship between statisticians and market access professionals, exploring why these functions struggle to collaborate and, more importantly, how we can work together more effectively.

Manuel Nordeste is Vice-President at Fidelity Digital Assets and leads the business development team outside of the United States.In this episode, Manuel discusses the evolving landscape of Bitcoin and digital assets, focusing on market sentiment, institutional interest, and the role of Fidelity Digital Assets. Exploring how regulatory changes and educational efforts have influenced corporate strategies and investor behaviour, particularly in relation to ETFs and the impact of companies like MicroStrategy. The episode was recorded on the 28th of Feb, 2025.Fidelity Digital Assets:- Bitcoin First (original): https://fwc.widen.net/s/kx6vn9hkfw/bitcoin-first- Bitcoin First (updated): https://fwc.widen.net/s/vbgwdtmnrf/1012662.6.0---fdas-bitcoin-first-revisited-v1- 2025 Look Ahead: https://fwc.widen.net/s/zrvf5hfjfs/fda-2025-look-ahead-report---final- Manuel Nordeste: https://www.linkedin.com/in/mnordeste/----Jordan's Bitcoin Products and Event Links:

In this episode of The MedTech Talent Lab, host Mitch Robbins sits down with April Spillane, VP of Market Access & Reimbursement at Intrinsic Therapeutics. With over 15 years in the industry—10 of those dedicated to spine—April shares her unique career trajectory, from clinical and business development to leading market access strategies at a high level.She opens up about the challenges of balancing a demanding career with motherhood, the leadership lessons she's learned along the way, and what it truly takes to thrive in market access and reimbursement. April also discusses the evolving healthcare landscape, the complexities of payer policies, and why persistence is key in the fight for patient access to cutting-edge technologies.Whether you're a MedTech leader, aspiring executive, or just curious about the behind-the-scenes battles to bring life-changing medical innovations to market, this episode is packed with valuable insights.Listen now to hear how April is shaping the future of MedTech access and advocacy!

Lisa Mullett, Senior Vice-President of Sumitomo Pharma America, gives insights into the importance of diversity in companies and patient trials, stepping out of your comfort zone to further your career, and accelerating development with AI. Get full access to NPC Healthbiz Weekly at healthbiz.substack.com/subscribe

Have you ever wondered why so many new drugs fail even after years of research and billions in investment? In this episode, we dive deep into the challenges of drug commercialization, the role of AI in pharma, and the biggest mistakes companies make before going to market.Our guest, Dan Cummings, is a leading expert in go-to-market strategy, having worked with top health tech, medtech, and biotech startups. He shares insider insights on why even successful clinical trials don't guarantee a product's success and how companies can improve their chances.We also explore:- The shocking statistics behind drug approvals - Why less than a third of new drugs in 2025 will meet expectations- The #1 mistake pharma companies make before launch - How AI is transforming drug development & commercialization - What makes some drugs cost millions of dollars, while others are much cheaper This episode is packed with industry insights, expert opinions, and bold predictions about the future of pharmaceuticals.Chapters:00:00 Introduction03:54 The Challenges of Drug Commercialization05:35 Market Access & Value-Based Pricing12:00 Predictions for 2025 Drug Approvals13:23 The Role of AI in Pharma16:59 Why Most Drug Launches Miss Expectations18:25 Lessons from Biotech Success Stories23:46 The Future of Pharma & Go-to-Market Strategies29:31 How Companies Can Improve Their Launch Success35:56 Final Thoughts & Takeaways

This week, our guest is Anne Applebaum, a Pulitzer Prize-winning journalist, historian, and New York Times bestselling author. Her latest book, Autocracy Inc.: The Dictators Who Want to Run the World, explores the global rise of authoritarianism.On February 6th, 2025, Anne spoke at the University of Calgary's Haskayne School of Business annual PETRONAS International Energy Speaker Series. This episode was recorded live at the event.Jackie Forrest moderated the discussion with Anne Applebaum, which covered a wide range of topics, including the timing of her new book, the Trump administration's early actions and executive orders, and the recent deterioration of Canadian-US relations.Please review our disclaimer at: https://www.arcenergyinstitute.com/disclaimer/ Check us out on social media: X (Twitter): @arcenergyinstLinkedIn: @ARC Energy Research Institute Subscribe to ARC Energy Ideas PodcastApple PodcastsAmazon MusicSpotify 

Join Isabel and Jade for part two of their World Cancer Day special for 2025, where guest Martin Price, Vice President, Health Economics, Market Access and Reimbursement, EMEA, Johnson & Johnson, uncovers more of his insights into the oncology space.  In this instalment, Martin shares his thoughts on improving access to innovative cancer medicines, improving public trust toward the industry and his personal leadership style.  A little more on GOLD's guest… Martin Price is Vice President for Health Economics, Market Access and Reimbursement in Europe, the Middle East and Africa, Johnson & Johnson, a role he has held for the past eight years. He leads the teams responsible for achieving optimal and accelerated market access, at a fair and value-based price, for Johnson & Johnson's new products and indications. Prior to this, Price worked in Johnson & Johnson's UK affiliate, latterly as director of external affairs, where he was responsible for market access, communications and government affairs. He joined Johnson & Johnson in 2001 from GlaxoSmithKline, where he began his career as senior health-outcomes manager. 

Join Isabel and Jade as they present a special World Cancer Day 2025 edition of the podcast. They are joined by Martin Price, Vice President, Health Economics, Market Access and Reimbursement, EMEA, Johnson & Johnson.  In this first instalment of the conversation, Martin and Jade discuss this year's theme ‘United by Unique', the increasing importance of real-world evidence in oncology and improving access to innovative cancer medicines.   A little more on GOLD's guest… Martin Price is Vice President for Health Economics, Market Access and Reimbursement in Europe, the Middle East and Africa, Johnson & Johnson, a role he has held for the past eight years. He leads the teams responsible for achieving optimal and accelerated market access, at a fair and value-based price, for Johnson & Johnson's new products and indications. Prior to this, Price worked in Johnson & Johnson's UK affiliate, latterly as director of external affairs, where he was responsible for market access, communications and government affairs. He joined Johnson & Johnson in 2001 from GlaxoSmithKline, where he began his career as senior health-outcomes manager.

The opening of Mexico to fresh table stock exports has created significant benefits for U.S. producers, Mexican consumers and even Mexican growers as demand for potatoes increases. During Potato Expo 2025, we brought together four industry experts to provide valuable insights on the challenges and opportunities surrounding U.S. potato exports. The episode highlights the 25-year journey to open the Mexican market for U.S. potatoes, demonstrating the collaboration between industry leaders and government officials. • Overview of the 25-year effort to gain market access • Strategies by Potatoes USA to educate Mexican consumers • Differences in consumer preferences and purchasing power analysis • Challenges in distribution channels and traditional market dynamics • Importance of consumer sampling and education in driving demand • Ongoing phytosanitary concerns and mitigation strategies • Outlook on growth potential and market share for US potatoes in MexicoGuests:Kim Breshears, Chief Marketing Officer, Potatoes USAKam Quarles, CEO, National Potato CouncilLuis Moreno, CEO, Grupo PMMatt Lantz, Senior Vice President of Global Access, Bryant Christie Inc.This podcast is possible thanks to our presenting sponsor, Syngenta. Delivering solutions to help producers face the potato industry's complex challenges, Syngenta provides growers with unmatched field expertise along with an array of effective products. Explore syngenta-us.com/spud-doctor to discover solutions for your potato-growing obstacles. 

In this episode of Molecule to Market, you'll go inside the outsourcing space of the global drug development sector with Dean McAlister, Executive Vice President at Inizio Biotech. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Dean, covering: The evolving dynamics within the life sciences sector and how they are shaping outsourcing strategies Key insights and trends from J.P. Morgan week, including challenges and opportunities for CROs and CDMOs The Impact of cautious optimism on Business Development teams and commercial strategy in the current market Climate Why 2025 may be a year of incremental growth and how contract service providers can position themselves for success amidst swirling market headwinds The importance of strategic customer engagement and brand positioning for smaller, specialized players to gain an edge over global CDMO giants Dean brings a wealth of experience from his leadership role at Inizio Biotech, where he focuses on driving growth, innovation, and operational excellence. Prior to joining Inizio, he held executive leadership roles at AstraZeneca in US Commercial Sales and Market Access, leading teams of up to 1,100 people and overseeing high-impact strategies in a highly competitive environment.   Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We'd also appreciate a positive rating!   Molecule to Market is also sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

The Chinese Commerce Ministry says it will boost opening-up and ease market access this year. Officials say the country will steadily advance the opening-up of the service industry after lifting all foreign investment restrictions in the manufacturing sector.

The threat of tariffs on Canada's trade with the United States continues to be top of mind, with Alberta's Premier, Danielle Smith, recently returning from Mar-a-Lago after meeting with President-elect Donald Trump over the weekend.This week on the podcast, our guest is Marcus Rocque, Vice President at the ARC Energy Research Institute. Marcus joins Jackie and Peter in discussing the potential for Canadian oil and gas tariffs and the possible market implications. They review Canada's trade surplus with the United States, which is smaller than Donald Trump often claims, and whether the trade surplus is the only motivation for his threats to Canada. Next, they consider the amount of oil and natural gas Canada sends to the United States and the US's ability to substitute some of this consumption with alternative supply. Finally, they consider how the tariffs could impact US consumers and Canadian oil and gas producers.Content referenced in this podcast:Polymarket: “Will Trump impose 25% tariff on Mexico/Canada?” Please review our disclaimer at: https://www.arcenergyinstitute.com/disclaimer/ Check us out on social media: X (Twitter): @arcenergyinstLinkedIn: @ARC Energy Research Institute Subscribe to ARC Energy Ideas PodcastApple PodcastsAmazon MusicSpotify 

In this episode of the NASP Podcast, Sheila Arquette, President & CEO of NASP, speaks with Bridgette Kanz Schroader, PharmD, MPA, BCOP, Associate Director within the Medical Affairs Strategy & Publications team at Market Access & Healthcare Consulting, part of Cencora, and Laurie Fayzio, Head, Manufacturer Strategy, at FormularyDecisions. They explore the changing landscape of digital communication between biopharma companies and healthcare decision makers (HCDMs) and delve into 3 key topics that are crucial for effective engagement in the digital era with key decision makers: research on how HCDMs are utilizing digital resources and valuable insights into their preferences, how biopharma companies are adapting to meet the evolving needs of HCDMs in a post-pandemic peak era, and innovative strategies to optimize digital communications and the implications for stakeholder relationships.

Episode 44 - Shay Speakman-Brown, Head of Market Access for Dexcom UK and Ireland, brings extensive experience in healthcare, excelling in business strategies, market expansion, and managing multi-franchise projects. Disclaimer: Please note that all information and content on the UK Health Radio Network, all its radio broadcasts and podcasts are provided by the authors, producers, presenters and companies themselves and is only intended as additional information to your general knowledge. As a service to our listeners/readers our programs/content are for general information and entertainment only.  The UK Health Radio Network does not recommend, endorse, or object to the views, products or topics expressed or discussed by show hosts or their guests, authors and interviewees.  We suggest you always consult with your own professional – personal, medical, financial or legal advisor. So please do not delay or disregard any professional – personal, medical, financial or legal advice received due to something you have heard or read on the UK Health Radio Network.

In this episode, Steve Roest, CEO of PocDoc and host of the HealthTech Hour speaks to Shay Speakman-Brown, the Head of Market Access for the UK and Ireland at Dexcom about the revolution in diabetes care, the human stories behind it and the technology that has driven it - and what's coming next. Dexcom were the first company in the world to invent the continuous glucose monitor and are the first to get a continuous glucose monitor regulated for over the counter purchases. Shay is a leader in the field of technology-driven diabetes care.

In this edition of the Industry Matters podcast, Heather Trumm, Director of Wound Care, at VGM & Associates talks to Trish Skiendziel, Director, Market Access, Nestle Health Science, about value-based care. As payers reduce reimbursement rates, they are looking to providers to prove their worth. Listen in as Heather and Trish talk about this large topic, how HMEs can prove their worth, why it's important to combat declining reimbursement rates, and what resources are available to our members. Resources Referenced for our VGM MembersVGM Government Relations TeamVGM members-only portal with resources and tools for providersEnteral Guide for entering the market as an HME provider Nestlemedicalhub.com - resources available that showcases the value of the intervention with specialized nutrition and the impact on outcomes and Cost of Care  Resources For Payers: Malnutrition | Nestlé Medical HubAAHomecare Enteral Infographic and Value of HMEAAHomecare Enteral White PaperNestle Toolkit to Take to Their Payers - contact your Nestle RepresentativeAAHomecare Advocacy

We love to hear from our listeners. Send us a message. On this episode of the Business of Biotech, Bill and Melinda Gates Medical Research Institute's (Gates MRI) Dr. Claire Wagner joins us to share insights into her work as head of Corporate Strategy and Market Access there. She shares the development of her North Star while working with the incomparable Dr. Paul Farmer in Rwanda, and how that experience translates to the growth of a biopharmaceutical company taking big swings for grossly underserved populations. We discuss the nuances assoiated with setting strategy and enabling product access in a unique not-for-profit setting, and how, perhaps counterintutively, the Institute's work fits synergistically into an ultra-competitive for-profit biopharma landscape. Access this and hundreds of episodes of the Business of Biotech videocast under the Listen & Watch tab at bioprocessonline.com. Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: matt.pillar@lifescienceconnect.comFind Matt Pillar on LinkedIn: https://www.linkedin.com/in/matthewpillar/

In this episode, Peter Nguyen, Director of Market Access at PRO-spectus, discusses his journey fueled by positivity and genuine enthusiasm. Starting as a part-time employee, Peter grew to become a leader known for his empathy and resilience. We learn how his unique approach, rooted in kindness and optimism, has helped PRO-spectus thrive while ensuring patient needs are prioritized. His story is one of dedication and purpose, offering insights on the impact of positivity in leadership.Listen to our podcasts at:Podcast: https://www.shorecp.university/podcastsThere you will also find our other "Everyday Heroes" episodes, alongside our series "Microcap Moments" and "Bigger. Stronger. Faster.", highlighting the people and stories that make the microcap space unique.Other ways to connect:Blog: https://www.shorecp.university/blogShore Capital University: https://www.shorecp.university/Shore Capital Partners: https://www.shorecp.com/This podcast is the property of Shore Capital Partners LLC. None of the content herein is investment advice, an offer of investment advisory services, nor a recommendation or offer relating to any security. See the “Terms of Use” page on the Shore Capital website for other important information.

In this episode, Peter Nguyen, Director of Market Access at PRO-spectus, discusses his journey fueled by positivity and genuine enthusiasm. Starting as a part-time employee, Peter grew to become a leader known for his empathy and resilience. We learn how his unique approach, rooted in kindness and optimism, has helped PRO-spectus thrive while ensuring patient needs are prioritized. His story is one of dedication and purpose, offering insights on the impact of positivity in leadership.Listen to our podcasts at:Podcast: https://www.shorecp.university/podcastsThere you will also find our other "Everyday Heroes" episodes, alongside our series "Microcap Moments" and "Bigger. Stronger. Faster.", highlighting the people and stories that make the microcap space unique.Other ways to connect:Blog: https://www.shorecp.university/blogShore Capital University: https://www.shorecp.university/Shore Capital Partners: https://www.shorecp.com/This podcast is the property of Shore Capital Partners LLC. None of the content herein is investment advice, an offer of investment advisory services, nor a recommendation or offer relating to any security. See the “Terms of Use” page on the Shore Capital website for other important information.

Thanks for tuning in to this Wednesday edition of RealAg Radio. Host Shaun Haney is joined by: Neil Townsend with Grainfox with a grain market outlook; Stephen Heckbert with the Canadian Pork Council on policy priorities for the pork industry and reaction to the U.S. election results; Hear some of the results from the October… Read More

Thanks for tuning in to this Wednesday edition of RealAg Radio. Host Shaun Haney is joined by: Neil Townsend with Grainfox with a grain market outlook; Stephen Heckbert with the Canadian Pork Council on policy priorities for the pork industry and reaction to the U.S. election results; Hear some of the results from the October… Read More

Welcome to the Alfalfa Podcast

With the first round of CMS price negotiations behind us, and the next list of targets to be released in February 2026, it's clear that theorized implications from the Inflation Reduction Act are becoming realities for the life sciences industry. In this episode, Jen and Mindy are joined by Putnam Associates Partner, Scott Briggs, to explore how companies can navigate the new pricing pressures and negotiation frameworks while continuing to innovate and ensure patient access to critical therapies.For more information about Putnam's work in Value, Pricing and Access, visit their website: https://www.putassoc.com/our-expertise/value-pricing-access/For more information about Vynamic's work in Market Access, visit: https://vynamic.com/what-we-do/health-industry/life-sciences/market-access/Podcast Tags: healthcare, life sciences, product launch, market access, drug pricing, life sciences trendsPanel – Scott Briggs, Mindy McGrath, Jen BurkeResearch & Production – Scott Briggs, Mindy McGrath, Jen BurkeRecording & Editing – Mike Liberto, Rachel SkoneckiFor additional discussion, please contact us at TrendingHealth.com or share a voicemail at 1-888-VYNAMIC.

In this episode, we sit down with leading Market Access experts and members of ACCESS Forum to compare and contrast the drug pricing and access systems worldwide and the US. Our discussion delves into the distinct approaches taken by government vs. private markets, examining how regulatory environments, pricing controls, and reimbursement processes impact patient access to innovative therapies. We explore the challenges each approach faces, from cost pressures to affordability and access, and how they balance the interests of patients, governments, and pharmaceutical companies. Join us for a deep dive into how the global healthcare landscape is evolving and what lessons can be learned. Nikos Maniadakis, Ph.D., Professor, Health Management & Policy, University of West AtticaKimberly Baldwin, Senior Vice President, Value & Access, Ipsen BiopharmaceuticalsFauzea Hussain, Vice President, Public Policy, McKessonCMS (Centers for Medicare & Medicaid Services)European Medicines AgencyHealth technology assessments (HTAs)IRA (Inflation Reduction Act)MedicaidMedicareNational Institute of Clinical Excellence (NICE)NCCN guidelinesP&T committee (Pharmacy and Therapeutics Committee)PAP (Patient Assistance Program)Part B (Medicare)Part D (Medicare)Pharmacy Benefit Managers (PBMs)Quality-Adjusted Life Years TricareVeterans AdministrationMedical terminology referenced in this episode: Cell and gene therapies (CGT) Insulin Orphan drugs Questions or comments?Email us at comments@prescriptionforbetteraccess.com.

Dr. Andreas Lysandropoulos, Senior Vice President and Global Therapeutic Head of Neurosciences, and Wyatt Gotbetter, Senior Vice President, Worldwide Access Consulting, join Bev Hope, Parexel's Marketing Strategy Director, in a podcast discussion of how sponsors can build a value proposition and market access strategy for novel neurological and psychiatric treatments. Neuroscience disorders present significant challenges, including incomplete scientific understanding, patients' unequal access to accurate diagnosis and prognosis, payers' focus on short-term clinical outcomes, a relative lack of patient-relevant endpoints, and collecting high-quality real-world evidence, to name a few. Our experts offer examples and insights on how to overcome obstacles and de-risk sponsors' access strategies.

美國的高藥價和高醫療支出世界知名，光是處方藥的支出，就佔了全球處方藥物市場的四成，其中十款藥物在 2022 年佔了 Medicare 將近20%的支出（500 億美元），因此最近被《降低通膨法案》（Inflation Reduction Act, IRA）鎖定，於協商後大砍藥價，有些藥甚至被砍到現在價格的兩折，並於 2026 年實施． 究竟在整條藥物價值鏈當中，有哪些關鍵環節來決定藥價和藥品給付呢？藥品福利管理機構（Pharmacy Benefit Manager, PBM）又在其中扮演什麼樣的角色？美國為什麼不像台灣一樣辦理全民健保呢？關於以上問題，我們很榮幸邀請到目前在 Takeda 藥廠擔任 Reimbursement & Contracting Strategy Lead 的 Mike Lee 來跟我們解析美國藥品錯綜複雜的給付系統，帶我們從更高的視角，一覽美國醫藥產業的運作體系全貌。  

Navigating the complexities of groundbreaking treatments can create headwinds. With innovations like Pulsed Field Ablation (PFA) at the forefront, challenges such as financial uncertainties, regulatory shifts, and global adoption become paramount. Join us for an insightful discussion on how global partners address these challenges, focusing on safety & efficacy, financial impacts, and clinical differentiation in areas where baseline data is scarce. Background on PFA: Pulsed Field Ablation (PFA) is a groundbreaking nonthermal energy source that is rapidly transforming atrial fibrillation (AF) treatment, affecting up to 38 million people worldwide. Unlike traditional heat or cold methods, PFA uses high-voltage electrical fields in microseconds for precise cell necrosis, marking a significant advancement in cardiology. Guests: - Juliane Ray, Global Head of Medtech Strategy, Clarivate (Moderator) - Annette Boyle, Editor, BioWorld MedTech - Dee Chaudhary, Principal Commercial Strategy Consulting, Clarivate - Pankhil Ghandhi, Senior Team Lead, Medtech Insights, Clarivate - David Begley, MD, Clinical Director in Cardiology, Royal Papworth HospitalSend us a message! Follow Medical Alley on social media on LinkedIn, Facebook, Twitter and Instagram.

We are at a major tipping point of scientific breakthroughs. There are accelerating the frontiers in neuroscience; there is a greater sense of hope, but delivering on that hope for patients and caregivers requires a new approach to market access. In this podcast episode, we will delve into the unique challenges of access strategies in neurology and psychiatry, the implications and the need for new approaches, and how to develop successful strategies.